\
&
Contact us
\
&
Contact us
Published on | 5 months ago
ProgrammesEIT Health has established an access2finance instrument to help promising start-ups with high-impact healthcare and life science solutions to secure capital and to scale up. This initiative aims to help young business prospects to prepare their investment materials, strengthen their value proposition, and get them investor-ready.
Find out more about the 'venture centre of excellence' initiative and its specific conditions on the dedicated EIT Health webpage.
Contact EIT Health Belgium-Netherlands for more info: bene.office@eithealth.eu
Background: The European Institute for innovation and technology (EIT) aims to bridge the gap between innovation and commercialisation. It does so by connecting the three pillars of the knowledge triangle (innovation, business creation and education) through the establishment of Knowledge and Innovation Communities (KICs). Currently, there are 9 different KICs, each forming a network of companies, universities, research centres and other organizations. These communities regularly launch calls for proposals to identify high-potential companies. EIT Health is one of these KICs .
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has published a new round of calls under the Digital Europe programme. The submission period for the following call topics will open on 21 April 2026: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
